Evidence map›Paper›PMID 39218140›Full record

ArticleProgress in neurobiology2024

Distinct 5-HT receptor subtypes regulate claustrum excitability by serotonin and the psychedelic, DOI.

Tanner L Anderson, Jack V Keady, Judy Songrady, Navid S Tavakoli, Artin Asadipooya, Ryson E Neeley, Jill R Turner, Pavel I Ortinski

Abstract read
In one paragraph

Article in Progress in neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Serotonin and psilocybin activate 5-HTNature communications · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanner L AndersonUniversity of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY 40536, United States.
Jack V KeadyUniversity of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Lexington, KY 40536, United States.
Judy SongradyUniversity of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Lexington, KY 40536, United States.
Navid S TavakoliUniversity of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY 40536, United States.
Artin AsadipooyaUniversity of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY 40536, United States.
Ryson E NeeleyUniversity of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY 40536, United States.
Jill R TurnerUniversity of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Lexington, KY 40536, United States.
Pavel I OrtinskiUniversity of Kentucky, College of Medicine, Department of Neuroscience, Lexington, KY 40536, United States. Electronic address: pavel.ortinski@uky.edu.

Funding

Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
Functional and Genomic Signatures of Escalated Fentanyl UseR01DA053070 · NIDA · UNIVERSITY OF KENTUCKY · PI BARDO, MICHAEL T, ORTINSKI, PAVEL IVANOVICH · 2021 to 2025
$3.2M
Dynamic Signaling of NRG3-ErbB4 in the Hippocampus Mediates Nicotine Withdrawal PhenotypesR01DA044311 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI TURNER, JILL R. · 2018 to 2022
$1.9M
Neural microcircuit selection by astrocyte signaling following cocaine exposureR01DA041513 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ORTINSKI, PAVEL IVANOVICH · 2017 to 2021
$1.6M
Regulation of cocaine use by astrocyte voltage-gated channelsR21DA060354 · NIDA · UNIVERSITY OF KENTUCKY · PI ORTINSKI, PAVEL IVANOVICH · 2024 to 2025
$406k
Claustrum serotonin and spike-timing plasticity associated with cognitive deficits after cocaineF31DA055445 · NIDA · UNIVERSITY OF KENTUCKY · PI ANDERSON, TANNER · 2023 to 2025
$58k
NIDA NIH HHS F31 DA055445NIDA NIH HHS R01 DA041513NIDA NIH HHS R01 DA044311NIDA NIH HHS R01 DA053070NIDA NIH HHS R21 DA060354NIDA NIH HHS T32 DA035200
6 · The paper itself

Abstract

Recent evidence indicates that neuronal activity within the claustrum (CLA) may be central to cellular and behavioral responses to psychedelic hallucinogens. The CLA prominently innervates many cortical targets and displays exceptionally high levels of serotonin (5-HT) binding. However, the influence of serotonin receptors, prime targets of psychedelic drug action, on CLA activity remains unexplored. We characterize the CLA expression of all known 5-HT subtypes and contrast the effects of 5-HT and the psychedelic hallucinogen, 2,5-dimethoxy-4-iodoamphetamine (DOI), on excitability of cortical-projecting CLA neurons. We find that the CLA is particularly enriched with 5-HT2C receptors, expressed predominantly on glutamatergic neurons. Electrophysiological recordings from CLA neurons that project to the anterior cingulate cortex (ACC) indicate that application of 5-HT inhibits glutamate receptor-mediated excitatory postsynaptic currents (EPSCs). In contrast, application of DOI stimulates EPSCs. We find that the opposite effects of 5-HT and DOI on synaptic signaling can both be reversed by inhibition of the 5-HT2C, but not 5-HT2A, receptors. We identify specific 5-HT receptor subtypes as serotonergic regulators of the CLA excitability and argue against the canonical role of 5-HT2A in glutamatergic synapse response to psychedelics within the CLA-ACC circuit.

Indexed as

AmphetaminesClaustrumExcitatory Postsynaptic PotentialsHallucinogensReceptors, SerotoninSerotoninAnimalsMaleMiceMice, Inbred C57BLNeurons4-iodo-2,5-dimethoxyphenylisopropylamineAmphetaminesHallucinogensReceptors, SerotoninSerotonin2,5-dimethoxy-4-iodoamphetamine (DOI)5-HT2A5-HT2CClaustrumElectrophysiologyPsychedelicsSerotonin

Identifiers

PMID39218140
PMCPMC11444019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.